Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

• ClinicalTrials.gov Identifier: NCT00093080
• Recruitment Status: Completed
• First Posted: October 4, 2004
• Last Update Posted: February 13, 2015
• Sponsor: Merck Sharp & Dohme LLC
• Collaborator: Ariad Pharmaceuticals
• Information provided by (Responsible Party): Merck Sharp & Dohme LLC

Tracking Information

• First Submitted Date: September 30, 2004
• First Posted Date: October 4, 2004
• Last Update Posted Date: February 13, 2015
• Study Start Date: October 2004
• Actual Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: January 23, 2013): Number of participants with Clinical Benefit Response (CBR) Using Response Criteria in Solid Tumors (RECIST) [ Time Frame: Day 1 up to 4 years or discontinuation from study ]
• Original Primary Outcome Measures: Not Provided

Current Secondary Outcome Measures (submitted: January 23, 2013)

• Time to Tumor Progression [ Time Frame: Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) ]
• Progression Free Survival [ Time Frame: Day 1 to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) ]
• Overall Survival [ Time Frame: Day 1 to the date of death, or the date of last contact (up to 4 years) ]
• Duration of Response [ Time Frame: Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) ]
• Number of participants experiencing adverse events [ Time Frame: From first dose up to 30 days after last dose (up to 1 year) ]
• Number of participants who discontinued study drug due to adverse events [ Time Frame: From first dose up to the last dose (up to 1 year) ]
• Mean ridaforolimus blood levels within 5 minutes post intravenous infusion [ Time Frame: Day 1 and Day 5 of Cycle 1 ]

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
• Official Title: A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma
• Brief Summary: The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Leiomyosarcoma
• Liposarcoma
• Osteosarcoma
• Sarcoma, Soft Tissue
• Metastases

Intervention

Drug: ridaforolimus

12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks

Other Names:

• deforolimus (until May 2009)
• AP23573
• MK-8669

Study Arms

Experimental: Ridaforolimus

12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks

Intervention: Drug: ridaforolimus

• Publications *: Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7. Erratum in: J Clin Oncol. 2017 Aug 10;35(23):2722.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: July 26, 2011): 216
• Original Enrollment (submitted: June 23, 2005): 176
• Actual Study Completion Date: November 2008
• Actual Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Patients ≥15 years of age with metastatic and/or unresectable sarcomas of the following histological subgroups: Bone sarcomas, such as osteosarcoma and Ewings sarcoma; Leiomyosarcoma; Liposarcomas; Any other soft tissue sarcoma except gastrointestinal stromal tumors (GIST). Patients with well-differentiated liposarcoma or desmoid tumors must have demonstrated progressive disease within the previous 6 months
• Presence of at least one measurable lesion that: Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral computerized tomography (CT) scan (or otherwise at least twice the reconstruction interval for CT or magnetic resonance imaging [MRI] scans)
• Eastern Cooperative Oncology Group (ECOG) performance status ≤1
• Minimum life expectancy of 3 months
• Adequate renal and hepatic function, as specified in the protocol
• Adequate bone marrow function, as specified in the protocol
• Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL
• Male and female patients who are not surgically sterile or postmenopausal must agree to use reliable methods of birth control for the duration of the study until 30 days after the last dose of study drug
• Able to understand and give written informed consent

Exclusion Criteria:

• Women who are pregnant or lactating
• Presence of brain metastases
• Prior therapy with rapamycin, rapamycin analogues or tacrolimus
• Prior anticancer treatment (chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of ridaforolimus
• Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by National Cancer Institute (NCI) toxicity criteria)
• Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
• Known or suspected hypersensitivity to drugs formulated with polysorbate 80 (Tween) or any other excipient contained in the study drug
• Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)
• Significant uncontrolled cardiovascular disease
• Active infection requiring systemic therapy
• Known human immunodeficiency virus (HIV) infection
• Treatment with any investigational agent within 4 weeks prior to the first dose of ridaforolimus
• Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for 2 weeks prior to first planned dose of study drug
• Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of ridaforolimus
• Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 15 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided
• Removed Location Countries: France, United States

Administrative Information

• NCT Number: NCT00093080
• Other Study ID Numbers: 8669-018; AP23573-04-202 ( Other Identifier: Ariad Pharmaceuticals, Inc. ); 2004-002231-92 ( EudraCT Number )
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Merck Sharp & Dohme LLC
• Original Responsible Party: Not Provided
• Current Study Sponsor: Merck Sharp & Dohme LLC
• Original Study Sponsor: Ariad Pharmaceuticals
• Collaborators: Ariad Pharmaceuticals
• Investigators: Not Provided
• PRS Account: Merck Sharp & Dohme LLC
• Verification Date: February 2015